Quoin Pharmaceuticals, Ltd. (QNRX) Key Metrics
QNRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $18.7M
- Enterprise value
- $2.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.75
QNRX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsQNRX returns How much profit the business earns on the capital it uses.
QNRX financial health Debt, liquidity and how easily interest is covered.
QNRX efficiency & capital use Working capital cycle and where the cash goes.
QNRX valuation history
QNRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
QNRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
QNRX cash returned to shareholders
QNRX price vs earnings per share
QNRX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $21.6M | — | — | — | — | — | — | — | — | — |
| Enterprise value | −$3.80B | — | — | — | — | — | — | — | — | — |
| Price / book | 1.6 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −73.1% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −62.6% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $14.43 | $22.79 | $171.68 | $596.40 | $9,555.00 | $45,360.00 | $46,620.00 | $220,500.00 | $735,000.00 | $324,450.00 |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$10.55 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$9.04 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$9.04 | — | — | — | — | — | — | — | — | — |
| Cash per share | $2,548.24 | — | — | — | — | — | — | — | — | — |
| Book value per share | $8.76 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | −$247.09 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 1.5M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −141.6% | −120.6% | −132.9% | −232.7% | — | — | −38.9% | 334.6% | 158.5% | 303.3% |
| Return on assets (ROA) | −87.6% | −64.3% | −65.2% | −78.8% | −399.9% | −55.5% | −26.7% | 214.6% | 115.9% | 250.2% |
| Return on tangible assets | — | −58.9% | −75.0% | −68.2% | −251.1% | −450.5% | −30.3% | 277.3% | 116.3% | 173.8% |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | −0.43 | −0.49 | −0.25 |
| Financial health | ||||||||||
| Total debt | — | — | — | — | — | $1.2M | $310,654 | — | — | $15,070 |
| Cash & short-term investments | $3.82B | $14.1M | $10.7M | $12.9M | $7.5M | $323,832 | $5.2M | $4.8M | $8.0M | $8.0M |
| Net debt | −$3.82B | −$14.1M | −$10.7M | −$12.9M | −$7.5M | $889,481 | −$4.9M | −$4.8M | −$8.0M | −$8.0M |
| Debt / equity | — | — | — | — | — | — | 0.07 | — | — | 0.00 |
| Debt / assets | — | — | — | — | — | 0.88 | 0.05 | — | — | 0.00 |
| Net debt / EBITDA | — | — | — | — | — | — | — | −0.31 | −0.79 | −0.52 |
| Current ratio | 3.61 | 3.57 | 3.15 | 3.79 | 1.79 | 0.06 | 5.11 | 3.80 | 6.97 | 9.30 |
| Quick ratio | 3.61 | 3.57 | 3.15 | 3.79 | 1.79 | 0.06 | 5.11 | 3.80 | 6.97 | 9.30 |
| Interest coverage | — | — | — | -13.0 | -5.6 | -1.4 | -3.8 | — | — | — |
| Working capital | $14.5M | $10.7M | $7.7M | $9.8M | $3.6M | −$7.5M | $4.3M | $3.7M | $7.0M | $7.5M |
| Invested capital | −$3.80B | −$4.9M | −$5.0M | −$5.4M | −$6.8M | −$5.7M | −$635,785 | −$1.0M | −$2.6M | −$621,253 |
| Tangible asset value | −$370.2M | $8.7M | $5.1M | $6.7M | −$151,572 | −$7.5M | $3.3M | $3.7M | $5.4M | $7.4M |
| Net current asset value | $12.7M | $8.4M | $4.8M | $6.3M | −$501,572 | −$7.5M | $3.5M | $3.2M | $4.9M | $7.0M |
| Graham net-net per share | $2,543.39 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $65.3M | — | — | — | — | — | — |
| Share buybacks (net) | — | — | — | $14.8M | — | — | — | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 2.40 | 6.01 | 1.20 | 0.15 | 1.45 | 0.72 | 3.71 |
| Efficiency | ||||||||||
| Days payables outstanding | 3,925.3 | 2,601.5 | 1,997.5 | 2,692.3 | 3,236.6 | — | 227.6 | 1,056.7 | 1,470.0 | 959.7 |
| Receivables turnover | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.09 | 0.14 | 0.18 | 0.14 | 0.11 | — | 1.60 | 0.35 | 0.25 | 0.38 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | — | — | — | $67,552 | $64,188 | $121,290 | $110,033 |
| Average payables | $1.1M | $716,114 | $566,062 | $764,420 | $923,239 | — | $141,558 | $363,960 | $419,750 | $234,356 |
| Intangibles / total assets | 1,880.0% | 3.1% | 4.8% | 4.9% | 8.6% | 66.2% | 16.5% | 0.0% | 0.0% | 0.0% |
Computed from QNRX's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
QNRX valuation and financial ratios
Quoin Pharmaceuticals earned a return on equity of −141.6% in fiscal 2025.
See the QNRX income statement, the QNRX chart for price history, or the QNRX stock overview for the latest quote and news.
QNRX key metrics FAQ
What is Quoin Pharmaceuticals's return on equity?
Quoin Pharmaceuticals's return on equity (ROE) was −141.6% in fiscal 2025: net income of -$15.8 million on average shareholders' equity of $11.2 million.
What is Quoin Pharmaceuticals's free cash flow yield?
Quoin Pharmaceuticals generated -$13.5 million of free cash flow in fiscal 2025, a free cash flow yield of −62.6% on its market value at year-end ($21.6 million).
What is Quoin Pharmaceuticals's current ratio?
Quoin Pharmaceuticals's current ratio was 3.61 at the end of fiscal 2025: current assets were 3.61 times current liabilities.